O-CAL PRENATAL Rx
Generic Name and Formulations:
Vit. A 2500 IU, Vit. C 70mg, Vit. D 400 IU, Vit. E 30 IU, thiamine 1.5mg, riboflavin 1.6mg, niacin 17mg, pyridoxine 12mg, folic acid 1mg, Vit. B12 12mcg, calcium (as carbonate) 200mg, iron (as fumarate) 15mg, iodine (as potassium) 150mcg, magnesium (as oxide) 100mg, zinc (as oxide) 15mg, copper (as sulfate) 2mg; tabs.
Indications for O-CAL PRENATAL:
Nutritional supplement in pregnancy, prenatal, and postnatal periods.
1 tab daily.
Folic acid may mask pernicious anemia.
Iron, calcium block tetracycline absorption. Antagonizes levodopa.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC